Novartis to make commercial Carvykti; Recipharm divests seven facilities; Lilly’s Zepbound in shortage 

Wel­come to End­points News’ man­u­fac­tur­ing briefs, where we bring you es­sen­tial up­dates on new builds, col­lab­o­ra­tions, re­calls and more.

No­var­tis ex­tend­ed its deal with John­son & John­son and Leg­end Biotech to com­mer­cial­ly man­u­fac­ture Carvyk­ti, ac­cord­ing to a March 29 SEC fil­ing. No­var­tis will make the CAR-T ther­a­py at its fa­cil­i­ty in Mor­ris Plains, NJ, un­til the end of 2029. The orig­i­nal April 2023 deal saw No­var­tis make Carvyk­ti for clin­i­cal tri­als.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.